Methods for treating lysosomal acid lipase deficiency in patients
OwnerAnthony Quinninventor
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency. Methods of improving growth and liver function, increasing LAL tissue concentration, and increasing LAL activity in a human patient suffering from LAL deficiency are also provided.
Claims65
A method of treating a human patient with a lysosomal acid lipase (LAL) deficiency comprising administering recombinant human LAL to the patient, wherein the administration is sufficient to improve liver function.
A method of increasing LAL activity in a human patient with a LAL deficiency comprising administering recombinant human LAL to the patient, wherein the administration results in increased LAL activity in the patient.
A method of treating a condition associated with LAL deficiency in a patient in need thereof comprising administering an effective amount of exogenous LAL protein to the patient one time every 5 days to one time every 30 days.
A method of treating a condition associated with LAL deficiency in a patient in need thereof comprising administering to the patient a dose of 0.1 mg to 50 mg per kilogram of exogenous LAL, administered one time every 7 days to one time every 14 days.
A method of treating a condition associated with LAL deficiency in a patient in need thereof comprising administering to the patient a dose of about 0.1 mg to 5.0 mg per kilogram of exogenous LAL.
A method of treating Wolman Disease or CESD in a human patient in need thereof comprising administering to the patient a dose of about 0.1 mg to 50 mg per kilogram of exogenous LAL, administered one time every 5 days to one time every 30 days.
Dependencies are inferred from the claim text.